**Routine vaccinations during pregnancy: an update**

Christopher R Wilcox 1, Rebecca Rowe 2, Deborah C Mobley 3, Merlin Willcox 4, Christine E Jones 5

1: NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK

2: Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK

3: Victor Street Surgery, Shirley, Southampton, UK

4: Department of Primary Care and Population Sciences, Aldermoor Health Centre, University of Southampton, Southampton, UK

5: Faculty of Medicine and Institute for Life Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK

**Corresponding author**

* Dr Christopher Wilcox
* NIHR Clinical Research Facility, Southampton Centre for Biomedical Research, C Level West Wing, Mailpoint 218, Southampton General Hospital, Tremona Road, Southampton, SO16 6DY
* Email: christopher.wilcox@soton.ac.uk
* Telephone: 02381204956

**Keywords** - Antenatal vaccination; Maternal vaccination; Vaccination; Pregnancy; Influenza; Pertussis

**Why was this update developed?**

Antenatal vaccination is usually delivered in Primary Care, yet a recent survey highlighted that many UK GPs are not confident discussing vaccination with pregnant women, and would value concise guidelines  1.

**How does antenatal vaccination work?**

Antenatal vaccination boosts maternal antibody levels and therefore the amount of antibody transferred to the fetus.

**Rationale and effectiveness of antenatal vaccination**

*Pertussis (whooping cough)*

Recommendation: between 16-32 weeks of gestation

The UK antenatal pertussis vaccination programme was introduced following the 2012 pertussis outbreak, when >9000 individuals were infected and 14 infants died  2. Whilst numbers of cases have since reduced, rates of pertussis remain significantly higher than prior to 2012. A similar trend has been observed globally, and at least 14 countries have implemented similar recommendations  2.

Pertussis disproportionately affects young infants, who have the highest rates of disease, and are at highest risk of severe disease and death. Most cases occur in early childhood before completion of primary immunisation, and therefore antenatal vaccination provides effective protection during this ‘window-period’ of vulnerability.

Pertussis vaccination is <90% effective at protecting infants up to 2 months of age, and is 95% effective at preventing infant death from pertussis 2. The only deaths amongst infants born to vaccinated women have been in cases where the mother was vaccinated <10 days before delivery (leaving insufficient time for effective antibody transfer). Pertussis is currently only available as a combination vaccine (Boostrix-IPV in the UK) which also protects against tetanus, diphtheria and polio – which are safe to be given in pregnancy  3.

*Influenza*

Recommendation: any gestation during influenza season (usually October-March/April)

Pregnant women are at increased risk of severe disease from influenza, particularly during the third trimester. Influenza caused approximately 10% of UK deaths occurring in pregnant (or recently pregnant) women during 2009-2012  4. Furthermore, influenza can have severe consequences for the fetus and young infants, including pre-term birth, respiratory illness, and death  5.

Large trials have demonstrated approximately 50% reduction in cases of laboratory-confirmed influenza amongst vaccinated pregnant women and their infants (up to six months of age) 5, as well as a 50% reduction in infant hospitalisations due to influenza  6. Antenatal influenza vaccination has been recommended since 2009 in the UK, and is recommended by the World Health Organization (WHO)  5.

**What is the evidence of safety?**

* *Mild, self-limiting vaccine-related side effects are common*

Reactions at the vaccination site (such as pain and erythema) are common, and usually last 1-2 days. Mild fever, headaches, malaise and myalgia occur less commonly  3  7.

* *Severe allergic reactions are extremely rare*

Allergic reactions can occur to vaccine components, however serious reactions are extremely rare. A study of >25 million vaccine doses in adults and children demonstrated an anaphylaxis rate of 1.31 per million 8, and no evidence suggests the rate is higher during pregnancy. The life-threatening nature of anaphylaxis, however, necessitates that providers have resources in place for its immediate management.

* *No evidence of adverse pregnancy outcomes*

RCTs and observational studies, involving hundreds of thousands of mother-infant pairs, demonstrate no increased risk of maternal complications (including maternal death, hypertensive disorders, and caesarean section rates) or adverse fetal outcomes (including fetal death, malformations, growth restriction, or premature birth) associated with antenatal vaccination, compared to background rates  3  7.

* *No evidence of adverse infant neurodevelopmental outcomes*

Public concern has arisen over longer-term outcomes of vaccination, particularly with regards to autism. No evidence demonstrates any association with autism, including a recent study of 82,000 infants whose mothers received pertussis vaccination  9.

* *No evidence of risk associated with vaccine adjuvants*

Vaccine adjuvants, such as alum (aluminium), improve the immune response to vaccines.

* Alum is present at very low concentration in Boostrix-IPV (the pertussis-containing vaccine), the amount absorbed is extremely low, and no evidence shows adverse effects on cognitive development  10. Natural exposure to aluminium also occurs regularly  10.
* Thimerosal/Thiomersal (an ethylmercury-based preservative) is no longer used in UK vaccines, however no evidence of harm was demonstrated with its use.
* Formaldehyde may be present in influenza vaccines (trace amounts). Pork gelatine is not present in the vaccines recommended during pregnancy in the UK.

**Table 1: Other FAQs from pregnant women**

|  |  |
| --- | --- |
| *I was vaccinated during my last pregnancy. Should I get vaccinated again?* | Yes, influenza and pertussis vaccination is recommended in each pregnancy to ensure optimal protection |
| *Is there a chance that I, or my baby, could get flu or whooping cough from the vaccine?* | No, both are non-live vaccines and therefore cannot cause even mild forms of the infections |
| *I’m perfectly healthy. Why do I need the flu vaccine?* | Pregnant women are at increased risk of severe disease, and infection can have serious consequences for their unborn baby. The infant will also have increased protection against influenza during the first months of life. |
| *Can I have both vaccines on the same day?* | Yes, it’s safe to have both on the same day |
| *The Boostrix-IPV manufacturer leaflet says there is no information on its use in pregnancy?* | This statement is present becausevaccine clinical trials weren’t performed in pregnancy by the manufacturer prior to licensing. It is now recommended by the Department of Health as good evidence shows vaccination is safe and effective.  |
| *Isn’t it all to make money for drug companies?* | The studies confirming the safety/efficacy of vaccination have not been carried out by the manufacturers. |

**Further resources for:**

**1) Healthcare professionals**

* Public Health England (PHE) guidance
	+ https://www.gov.uk/guidance/pertussis-whooping-cough-immunisation-for-pregnant-women-resources-and-training#training-resource-on-pertussis-vaccination-in-pregnancy-for-health-professionals
	+ https://www.gov.uk/government/publications/influenza-vaccination-in-pregnancy-advice-for-healthcare-professionals
* Health Education England immunisation eLearning

(https://www.e-lfh.org.uk/programmes/immunisation/)

* Oxford Vaccine Knowledge Project (information on vaccines)

(vk.ovg.ox.ac.uk)

**2) Pregnant women**

* PHE leaflets
	+ https://www.gov.uk/government/publications/resources-to-support-whooping-cough-vaccination
	+ https://www.gov.uk/government/publications/flu-vaccination-leaflet-for-pregnant-women
* Oxford Vaccine Knowledge Project
* The MatImms mobile app (provides information and personalised vaccine schedules) (http://quicktech.imperialinnovations.co.uk/i/software\_apps/MatImms.html)

**References**

 1. Wilcox, C. R., Little, P. & Jones, C. E. Current practice and attitudes towards vaccination during pregnancy: a survey of general practitioners across England. *Submitted to Br J Gen Pract*

2. Amirthalingam G, Campbell H, Ribeiro S, et al. Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction. *Clinical infectious diseases* (2016) **63,** S236–S243.

3. Furuta M, Sin J, Ng E & Wang, K. Efficacy and safety of pertussis vaccination for pregnant women – a systematic review of randomised controlled trials and observational studies. *BMC Pregnancy Childbirth* (2017) **17,** 390.

4. UK. MBRRACE-UK 2014 Summary Report (Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK) 2019).

5. Madhi SA, Nunes MC. & Cutland CL. Influenza vaccination of pregnant women and protection of their infants. *New Eng J Med* (2014) **371,** 2340.

6. Poehling KA, Szilagyi PG, Staat MA, et al*.* Impact of maternal immunization on influenza hospitalizations in infants. *Am J Obstet Gynecol* (2011) **204,** S141–8.

7. Munoz F. Safety of influenza vaccines in pregnant women. *American Journal of Obstetrics and Gynecology* (2012) **207,** S33–S37.

8. McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol* (2016) **137,** 868–878.

9. Becerra-Culqui T, Getahun D, Chiu V, Sy L & Tseng H. Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. *Pediatrics* (2018) **142,** e20180120.

10. Karwowski M, Stamoulis C, Wenren LM, et al*.* Blood and Hair Aluminum Levels, Vaccine History, and Early Infant Development: A Cross-Sectional Study. *Acad Pediatr (2018)* **18,** 161–165.

**Conflict of Interests Statement**

CRW and CEJ are investigators for clinical trials done on behalf of their respective institutions, sponsored by various vaccine manufacturers, but receive no personal funding. RR is a vaccination specialist midwife.

**Funding Information**

CJ is supported by the IMmunising PRegnant women and INfants neTwork (IMPRINT), funded by the GCRF Networks in Vaccines Research and Development, which was co-funded by the MRC and BBSRC. The salary of MW is funded by the National Institute of Health Research (NIHR), under grant CL-2016-26-005.

**Author Contributions**

C Wilcox drafted the manuscript. All authors critically revised it and approved the final version.

**Acknowledgements**

None

**Ethical approval**

N/A